Skip to main content
SpringerLink
Log in

The Effects of Long Term Zidovudine Therapy and Pneumocystis carinii Prophylaxis on HIV Disease

A Review of the Literature

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

An Erratum to this article was published on 01 April 1995

Summary

Two lines of attack have been used against HIV-1 disease: (1) antiretroviral therapy (notably zidovudine) directed against the HIV-1 virus; and (2) chemoprophylaxis against end-stage diseases of HIV-1 infection, most notably against Pneumocystis carinii pneumonia. Many studies and clinical trials have found that zidovudine and P. carinii prophylaxis each significantly reduce short term morbidity and mortality from HIV-1 disease. However, these drugs have costs, adverse effects and (particularly with zidovudine) cumulative toxicity that suggest that their long term benefits may not necessarily be as great as their short term prospects.

Due to the pressing needs of the HIV-1 epidemic, social considerations and proven short term benefits, long term clinical trials of zidovudine and P. carinii prophylaxis employing untreated control groups are impossible. Thus, the long term benefits of these anti-AIDS therapies must be estimated from observational studies comparing those who choose to use those therapies and those who do not. Strong epidemiological biases and common statistical misanalyses of observational data occur, leading to seemingly contradictory results.

On the basis of the aggregate of short term clinical data and long term observational studies, zidovudine therapy taken either before or after AIDS delays the date of death by 12 months. If zidovudine therapy is initiated before AIDS, it may delay the date of diagnosis of AIDS by 12 months. However, issues of cost effectiveness, detrimental effects and optimal time to begin zidovudine therapy remain unresolved.

Limited observational study data suggest that P. carinii prophylaxis initiated before the onset of clinical AIDS will delay both the date of diagnosis of AIDS and the date of death by 9 months in North American men. The net benefits from P. carinii prophylaxis will be less in those who begin this treatment after a diagnosis of AIDS. Benefits from P. carinii prophylaxis will also probably be less in regions outside of North America, in particular underdeveloped countries, where P. carinii pneumonia is less common as an end-stage HIV-1-related illness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′-deoxythymidine (BW A509u): an antiviral agent inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096–100

    Article  PubMed  CAS  Google Scholar 

  2. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex: a double-blind placebo controlled trial. N Engl J Med 1987; 317: 185–91

    Article  PubMed  CAS  Google Scholar 

  3. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941–9

    Article  PubMed  CAS  Google Scholar 

  4. Spector SA, Kennedy C, McCutchan JA, et al. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. J Infect Dis 1989; 159: 822–8

    Article  PubMed  CAS  Google Scholar 

  5. Chaisson RE, Lenther MD, Allain JP, et al. Effect of zidovudine on serum human immunodeficiency virus core antigen levels: results from a placebo-controlled clinical trial. Arch Intern Med 1988; 148: 2151–3.

    Article  PubMed  CAS  Google Scholar 

  6. Pinching AJ, Helbert M, Reddle B, et al. Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. J Infect Dis 1989; 18: 33–40

    Google Scholar 

  7. Stambuck D, Hawkins D, Gizzard BG. Zidovudine treatment of patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: St Stephen’s Hospital experience. J Infect Dis 1989; 18: 41–51

    Google Scholar 

  8. Yarchoan R, Thomas RV, Graf man J, et al. Long-term administration of 3-azido-2′dideoxthymidine to patients with AIDS-related neurologic disease. Ann Neurol 1988; 23 Suppl.: 582–7

    Article  Google Scholar 

  9. Gray F, Belec L, Keohane C, et al. Zidovudine therapy and HIV encephalitis: a 10-year neuropathological survey. AIDS 1994; 8: 489–93

    Article  PubMed  CAS  Google Scholar 

  10. Schmidt FA, Bigley JW, McKinnis R, et al. Neurological outcome of zidovudine (AZT) treatment with AIDS and AIDS-related complex. N Engl J Med 318; 319: 1573-8

  11. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Int Med 1990; 1.12: 727–37

    Google Scholar 

  12. Fischl MA, Richman DD, Causey DM, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS related complex. JAMA 1989; 262: 2405–10

    Article  PubMed  CAS  Google Scholar 

  13. US Centers for Disease Control. Acquired immunodeficiency syndrome — United States. MMWR Morbid Mortal Wkly Rep 1987; 36: 522–6

    Google Scholar 

  14. Chaisson RE, Volberding PA. Clinical manifestations of HIV infection. In: Mandell GL, et al., editors. Principles and practices of infectious diseases. 3rd ed. New York: Churchill Livingstone, Inc., 1990

    Google Scholar 

  15. Hopewell PC. Diagnosis of Pneumocystis carinii pneumonia. Infec Dis Clin North Am 1988; 2: 409–18

    CAS  Google Scholar 

  16. Wilkes MS, Fortin AH, Felix JC, et al. Value of necropsy in acquired immunodeficiency syndrome. Lancet 1988; 2: 85–8

    Article  PubMed  CAS  Google Scholar 

  17. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonia. N Engl J Med 1977; 297: 1419–26

    Article  PubMed  CAS  Google Scholar 

  18. Montaner JSG, Lawson LM, Gervais A, et al. Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia: a randomized placebo-controlled study. Ann Intern Med 1991; 114: 948–53

    PubMed  CAS  Google Scholar 

  19. Girard PM, Landman R, Gaudebout C, et al. Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine treated AIDS patients. Lancet 1989; 1: 1348–53

    Article  PubMed  CAS  Google Scholar 

  20. Leong GS, Feigal D, Montgomery AB, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia: the San Francisco Community Prophylaxis Trial. N Engl J Med 1990; 323: 769–75

    Article  Google Scholar 

  21. Murphy RL, Lavelle JP, Allan JD, et al. Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose comparison study using an ultrasonic nebulizer. Am J Med 1991; 90: 418–26

    PubMed  CAS  Google Scholar 

  22. Hirschel B, Lazzarin A, Chopard P. A controlled study of inhaled pentamidine for primary prevention of P. carinii pneumonia. N Engl J Med 1991; 324: 1079–83

    Article  PubMed  CAS  Google Scholar 

  23. Kemper CA, Tucker RM, Lung OS, et al. Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. AIDS 1990; 4: 1145–8

    Article  PubMed  CAS  Google Scholar 

  24. Ruskin J, LaRiviere M. Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 1991; 337: 468–71

    Article  PubMed  CAS  Google Scholar 

  25. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo controlled clinical trial. N Engl J Med 1987; 317: 192–7

    Article  PubMed  CAS  Google Scholar 

  26. Dournon E, Matheron S, Rosenbaum W, et al. Effects of zidovudine in 305 consecutive patients with AIDS or AIDS-related complex. Lancet 1988; 2: 1297–1302

    Article  PubMed  CAS  Google Scholar 

  27. Langtry HD, Palmer KJ, Benfield P. Zidovudine: a review of the pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus. PharmacoEconomics 1993; 3: 309–37

    Article  PubMed  CAS  Google Scholar 

  28. Moore RD, Hidalgo J, Baretta JC, et al. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr 1994; 7: 349–54

    PubMed  CAS  Google Scholar 

  29. Decker CF, Masur H. Current status of prophylaxis for opportunistic infections in HIV-infected patients. AIDS 1994; 8: 11–20

    Article  PubMed  CAS  Google Scholar 

  30. Hirsch MS, D’Aquila RI. Therapy for human immunodeficiency virus type 1 infection. N Engl J Med 1993; 328: 1688–95

    Google Scholar 

  31. Abouya YL, Beaumel A, Lucas S, et al. Pneumocystis carinii pneumonia: an uncommon cause of death in African patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis 1992; 145: 617–20

    PubMed  CAS  Google Scholar 

  32. Fleming AF. Opportunistic infections in AIDS in developed and developing countries. Trans R Soc Trop Med 1990; 84 Suppl. 1: 1–6

    Article  Google Scholar 

  33. Batungwanayo J, Taelman H, Lucas S, et al. Pulmonary disease associated with the human immunodeficiency virus in Kisali, Rwanda. Am J Respir Crit Care Med 1994; 149: 1591–6

    PubMed  CAS  Google Scholar 

  34. Lundgren JD, Pederson C, Cluweck N, et al. Survival differences in European patients with AIDS: 1979-89. BMJ 1994; 308: 1068-B

    Article  PubMed  CAS  Google Scholar 

  35. Shuts R. And the band played on: politics, people and the AIDS epidemic. New York: Penquin Books, 1988

    Google Scholar 

  36. Brookmeyer R, Gail MH, Polk BF. The prevalent cohort study and the acquired immunodeficiency syndrome. Am J Epidemiol 1987; 126: 14–24

    PubMed  CAS  Google Scholar 

  37. Breslow NE, Day NE. Statistical methods in cancer research, Vol. II — the design and analysis of cohort studies. Lyons, France: International Agency for Research on Cancer (IARC), 1987

    Google Scholar 

  38. Miller Jr RG. Survival analysis. New York: John Wiley and Sons, 1981

    Google Scholar 

  39. Cox DR, Oakes D. Analysis of survival data. New York: Chapman and Hall, 1984

    Google Scholar 

  40. National Institute of Allergy and Infectious Diseases. AZT therapy for early HIV infection. Clin Courier 1990; 8 (5): 1–8

    Google Scholar 

  41. US Centers for Disease Control. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with HIV. MMWR Morbid Mortal Wkly Rep 1992; 41 (No. RR-4): 1-12

    Google Scholar 

  42. US Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against Pneumocystis carinii pneumonia among persons infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1993; 6: 46–55

    Google Scholar 

  43. Graham NMH, Zeger SL, Kuo V, et al. Zidovudine use in AIDS- free HIV-1 seropositive homosexual men in the Multicenter AIDS Cohort study (MACS), 1987–1981. J Acquir Immune Defic Syndr 1991; 4: 267–76

    PubMed  CAS  Google Scholar 

  44. Holmberg SD, Conley LJ, Buchbinder SD. Use of therapeutic and prophylactic drugs for AIDS by homosexual men in three US cities. AIDS 1993; 7: 699–704

    Article  PubMed  CAS  Google Scholar 

  45. Moore RD, Stanton D, Gopalan R, Chaisson R. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994; 330: 763–68

    Article  PubMed  CAS  Google Scholar 

  46. Abouker J-P, Swart AM. Preliminary analysis of the Concorde Trial [letter]. Lancet 1993; 341: 889–90

    Article  Google Scholar 

  47. Concorde Coordinating Committee. Concord MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871–81

    Article  Google Scholar 

  48. Lemp GF, Payne SF, Neal D, et al. Survival trends for patients with AIDS. JAMA 1990; 263: 402–06

    Article  PubMed  CAS  Google Scholar 

  49. Colford JM, Ngo L, Tager I. Factors associated with survival in human immunodeficiency virus infected patients with very low CD4 counts. Am J Epidemiol 1994; 139: 206–18

    PubMed  Google Scholar 

  50. Vella S, Giuliano M, Pezzotti P, et al. Survival of zidovudinetreated patients with AIDS compared with that of contemporary untreated patients. JAMA 1992; 267: 1232–6

    Article  PubMed  CAS  Google Scholar 

  51. Ragni MV, Kingsley LA, Zhou SJ. The effect of antiviral therapy on the natural history of human immunodeficiency virus infection in a cohort of hemophiliacs. J Acquir Immune Defic Syndr 1993; 5: 120–6

    Google Scholar 

  52. Osmond D, Charlekis E, Lang W, et al. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994; 271: 1083–7

    Article  PubMed  CAS  Google Scholar 

  53. Buira E, Gatell J, Miro J, et al. Influence of treatment with zidovudine (ZDV) on the long-term survival of AIDS patients. J Acquir Immune Defic Syndr 1992; 5: 737–42

    PubMed  CAS  Google Scholar 

  54. Robins JM, Blevins D, Ritter G, et al. Estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology 1992; 3: 319–36

    Article  PubMed  CAS  Google Scholar 

  55. Saah AJ, Hoover DR, He Y, et al. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1994; 7: 287–95

    PubMed  CAS  Google Scholar 

  56. Tu M, Meng X, Pagano M. Survival differences and trends in patients with AIDS in the United States. J Acquir Immune Defic Syndr 1993; 6: 1150–6

    PubMed  CAS  Google Scholar 

  57. Wilde MI, Langtry HD. Zidovudine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 46 (3): 515–78

    Article  PubMed  CAS  Google Scholar 

  58. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731–4

    Article  PubMed  CAS  Google Scholar 

  59. Nielsen C, Gotzsche PC, Nielsen CM, et al. Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy. Antiviral Research 1992; 18: 303–16

    Article  PubMed  CAS  Google Scholar 

  60. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1990; 3: 743–6

    PubMed  CAS  Google Scholar 

  61. Hamilton JD, Hartigan P, Simberkoff M. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992; 326: 437–43

    Article  PubMed  CAS  Google Scholar 

  62. Vella S, Giuliano M, Dally L. Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter cohort study. J Acquir Immune Defic Syndr 1994; 7: 31–8

    PubMed  CAS  Google Scholar 

  63. Cooper DA, Gatell JM, Kroon S. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329: 297–303

    Article  PubMed  CAS  Google Scholar 

  64. Graham NMH, Zeger SL, Park LP. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression to HIV-1 infection to AIDS. Lancet 1991; 328 (8762): 265–9

    Article  Google Scholar 

  65. Graham NMH, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992; 326: 1037–42

    Article  PubMed  CAS  Google Scholar 

  66. Longini IM, Clark WS, Karon JM. Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population based cohort. Am J Epidemiol 1993; 137: 1229–40

    PubMed  Google Scholar 

  67. Lundgren JD, Phillips AN, Pederson C, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994; 271: 1088–92

    Article  PubMed  CAS  Google Scholar 

  68. Bartlett JG. Zidovudine now or later [editorial]. N Engl J Med 1993; 329: 351–2

    Article  PubMed  CAS  Google Scholar 

  69. Phair J. Effectiveness of zidovudine in treatment of advanced HIV infection. JAMA 1994; 271: 1121–2

    Article  PubMed  CAS  Google Scholar 

  70. Lenderking WR, Gelber RD, Cotton RJ. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994; 330: 738–43

    Article  PubMed  CAS  Google Scholar 

  71. Nordic Medical Research Council’s HIV Therapy Group. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. BMJ 1992; 304: 13–7

    Article  Google Scholar 

  72. Fischl MA, Parker CB, Pettirelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 1009–14

    Article  PubMed  CAS  Google Scholar 

  73. Wu AW, Mathews WC, Brysk LT. Quality of life in a placebocontrolled trial of patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1990; 3: 683–90

    PubMed  CAS  Google Scholar 

  74. McKinney RE, Maha MA, Connor EM, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. N Engl J Med 1991; 324: 1018–25

    Article  PubMed  Google Scholar 

  75. Easterbrook PJ, Kerally JC, Creagh-Kirk T, et al. Racial and ethnic differences in outcome in zidovudine treated patients with advanced HIV disease. JAMA 1991; 266: 2713–8

    Article  PubMed  CAS  Google Scholar 

  76. Carr A, Tindall B, Denny R, Cooper D. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS 1992; 6: 165–71

    Article  PubMed  CAS  Google Scholar 

  77. Girard PM, Landman R, Gaudebout C. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993; 328: 1514–20

    Article  PubMed  CAS  Google Scholar 

  78. Schneider MME, Hoepelman AIM, Eiftnick S, et al. A controlled clinical trial of aerosolized pentamidine or trimethoprimsulfamethoxazole as a primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327: 1836–41

    Article  PubMed  CAS  Google Scholar 

  79. Phair J, Murioz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990; 322: 161–5

    Article  PubMed  CAS  Google Scholar 

  80. Bacchetti P, Osmond D, Chaisson RE, et al. Survival patterns of the first 500 patients with AIDS in San Francisco. J Infect Dis 1988; 157: 1044–7

    Article  PubMed  CAS  Google Scholar 

  81. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled clinical trial for trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992; 327: 1842–8

    Article  PubMed  CAS  Google Scholar 

  82. Klein N, Duncanson FP, Lenox T. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS 1992; 6: 301–5

    Article  PubMed  CAS  Google Scholar 

  83. May T, Beuscart C, Reynes B, et al. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective randomized controlled clinical trial. J Acquir Immune Defic Syndr 1994; 7: 457–61

    PubMed  CAS  Google Scholar 

  84. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmosis encephalitis in patients with AIDS. Ann Intern Med 1992; 117: 106–11

    PubMed  CAS  Google Scholar 

  85. Toma E, Faurnier S, Damont M. Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for pneumologists carinii pneumonia in AIDS: a randomized double-blind pilot trial. Clin Infect Dis 1993; 17 178–84

    Article  PubMed  CAS  Google Scholar 

  86. Hoover DR, Saah AJ, Bacellar H. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993; 329: 1922–6

    Article  PubMed  CAS  Google Scholar 

  87. Mallal SA, Martinez OP, French MA, et al. Severity and outcome of Pneumocystis carinii pneumonia in patients of known and unknown HIV status. J Acquir Immune Defic Syndr 1994; 7: 148–55

    PubMed  CAS  Google Scholar 

  88. Casale L, Gold H, Schecter C, et al. Decreased efficacy of inhaled pentamidine in the prevention of Pneumocystis carinii pneumonia among HIV-infected patients with severe immunodeficiency. Chest 1993; 103: 342–4

    Article  PubMed  CAS  Google Scholar 

  89. Jacobson LP, Kirby AJ, Polk S, et al. Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984–1991. Am J Epidemiol 1993; 138: 952–64

    PubMed  CAS  Google Scholar 

  90. Fleming P, Ciesielski C, Byers R, et al. Gender differences in reported AIDS-indicative diagnosis. J Infect Dis 1993: 168: 1–7

    Article  Google Scholar 

  91. Hoover DR, Graham NMH, Bacellar H, et al. Epidemiologic patterns of upper respiratory illness and P. carinii pneumonia in homosexual men. Am Rev Respir Dis 1991; 144: 756–9

    Article  PubMed  CAS  Google Scholar 

  92. Freeberg KA, Tostescum ANA, Cohen CJ, et al. Primary prophylaxis for Pneumocystis carinii in HIV-infected people with CD4 counts below 200/mm3: a cost-effective analysis. J Acquir Immune Defic Syndr 1991; 4: 521–31

    Google Scholar 

  93. Hessol NA, Koblin BA, Van Griensven JP, et al. Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trials cohort in Amsterdam, New York City and San Francisco, 1978-1991. Am J Epidemiol 1994; 139: 1077–87

    PubMed  CAS  Google Scholar 

  94. Hoover DR, Munoz A, He Y, et al. The effectiveness of interventions on incubation of AIDS as measured by secular increases within a population. Stat Med 1994; 13: 2127–39

    Article  PubMed  CAS  Google Scholar 

  95. Blum S, Singh TP, Gibbons E, et al. Trends in survival among persons with acquired immunodeficiency syndrome in New York City: the experience of the first decade of the epidemic. Am J Epidemiol 1994; 139: 351–61

    PubMed  CAS  Google Scholar 

  96. Spruance SL, Pavia AT, Peterson D, et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. Ann Intern Med 1994; 120: 360–8

    PubMed  CAS  Google Scholar 

  97. Fischl MA, Olson RM, Follansbee SE. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993; 118: 762–9

    PubMed  CAS  Google Scholar 

  98. Cooper DA, Pehrson PO, Pederson C, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS or AIDS-related complex: a double blind randomized trial, AIDS 1993; 7: 197–207

    Article  PubMed  CAS  Google Scholar 

  99. Stein D, Graham NMH, Park L, et al. The effect of interaction of acyclovir with zidovudine on progression to AIDS and survival. Ann Intern Med 1994; 121: 100–8

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Hygiene and Public Health, Johns Hopkins University, 624 North Broadway - Room 784, Baltimore, Maryland, 21205, USA

    Donald R. Hoover

Authors
  1. Donald R. Hoover
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03259146.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoover, D.R. The Effects of Long Term Zidovudine Therapy and Pneumocystis carinii Prophylaxis on HIV Disease. Drugs 49, 20–36 (1995). https://doi.org/10.2165/00003495-199549010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199549010-00003

Keywords

Search

Navigation